With interest we read the case report by Protsenko et al. on a metastatic BRAFV600E-mutated clear cell sarcoma responding to vemurafenib anti-BRAF targeted therapy [1] . We want to point out the crucial overlapping features between a melanoma and a clear-cell sarcoma from a theranostic point of view.
To the Editor,
With interest we read the case report by Protsenko et al. on a metastatic BRAFV600E-mutated clear cell sarcoma responding to vemurafenib anti-BRAF targeted therapy [1] . We want to point out the crucial overlapping features between a melanoma and a clear-cell sarcoma from a theranostic point of view.
Clear cell sarcoma represents about 1 % of all soft tissue sarcomas with an estimated yearly incidence of less than five cases per 10 million persons. With an annual incidence of some ten cases per 100,000 persons, malignant melanoma is about 200 times more frequent than clear cell sarcoma. Clear cell sarcoma is often intimately associated with tendons and aponeuroses and occurs in the extremities, with the foot/ankle accounts for 40 % of the cases. The head, the neck or the trunk regions are rarely affected. This tumor usually affects young adults in their 20s and 30s and presents as a slowly growing mass. In the report, Protsenko et al. report a very unusual clinical observation of a fast-growing tumor of the left lumbar area in a 46-year-old man.
From a pathological point of view, clear cell sarcomas and malignant melanomas share many histological and immunohistochemical features. Therefore, a melanoma can easily disguise itself as a clear cell sarcoma. The histopathological differential diagnosis between a malignant melanoma, especially a metastasis, and a clear cell sarcoma is not obvious. It is even more difficult when, as seen in many melanomas, the primary tumor remains unidentified despite of the metastatic evolution (so-called melanoma of an unknown primary origin). Differential diagnosis requires a search for rearrangements of EWSR1 (22q12) gene present in about 96 % of all clearcell sarcomas (according to the last WHO classification of soft tissue tumors) and absent in melanomas. Fluorescent in situ hybridization (FISH) with a EWSR1 break-apart probe allows the detection of the rearrangements of the gene independently of its partner. Reverse-transcriptase polymerase chain reaction (RT-PCR) with specific primers can be used to detect the EWSR1/ATF1 fusion due to t(12;22)(q13;q12) or the EWSR1/CREB1 fusion due to t(2;22)(q32.3;q12), present in about 90 and 6 % of the cases, respectively.
Protsenko et al. reported the absence of EWSR1/ATF1 and EWSR1/CREB1 fusions. As the method used to perform these analyses is not mentioned (presumably RT-PCR), we question whether a EWSR1 break-apart probe FISH analysis might have been an interesting method in the search of a yet unknown EWSR1 partner. Indeed, EWSR1 rearrangement is considered to be a hallmark of a clear-cell sarcoma and has been proven helpful in differentiating clear cell sarcomas from metastatic melanomas. On the other hand, BRAFV600E mutation Besides the distinction between a sarcoma and a melanoma, Protsenko et al. rightly points out the interest of treating this patient as having a BBRAF-mutated malignant clear cell tumor with melanocytic differentiation^. Oncologists and pathologists need to realize the interest of searching for BRAF mutations in these rare tumors of poor prognosis to allow access to targeted therapies.
